Importantly, many immune pathways were enriched, such as the Toll-like receptor signaling pathway and IL-17 signaling pathway, suggesting a potential regulatory role of ACP5 in SLE, except for type I IFN. This evidence concerns the gene ACP5 and systemic lupus erythematosus.